TY - JOUR
T1 - New frontiers in the pharmacological management of biliary tract carcinomas
T2 - the emerging role of drug conjugates
AU - Ocker, Matthias
AU - Mayr, Christian
AU - Huber-Cantonati, Petra
AU - Kiesslich, Tobias
AU - Neureiter, Daniel
N1 - Mayr, Kiesslich: Center of Physiology, Pathophysiology and Biophysics, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria; Huber-Cantonati: Institute of Pharmacy, Department of Pharmaceutical Biology and Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria; Kiesslich: Department of Internal Medicine I, Paracelsus Medical University/University Hospital Salzburg (SALK), Salzburg, Austria; Neureiter: Institute of Pathology, University Clinics Salzburg (SALK), Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
PY - 2025/5/3
Y1 - 2025/5/3
N2 - IntroductionBiliary tract cancer (BTC) is a human malignancy with a poor prognosis. However, significant progress has been made in understanding the molecular mechanisms of carcinogenesis, leading to the development of targeted therapy strategies in recent years. The challenge now is to develop new therapeutic concepts to further increase the efficacy of BTC treatments in the coming years.Areas coveredThis review covers the emerging and advanced approaches of highly sophisticated antibody-drug conjugates (ADCs) and non-ADCs, particularly in relation to BTC. Additionally, the potential advantages and disadvantages of ADCs and non-ADCs regarding toxicities, bioavailability, and efficacy are presented and discussed.Expert opinionGiven the poor prognosis of BTCs, new targeted and precision therapy strategies using drug conjugates - with and without antibodies as drug carriers - have the potential to overcome the limitations of conventional chemotherapy by improving treatment specificity and efficacy while reducing systemic toxicity. However, several open questions remain regarding ADCs and non-ADCs, including chemical design, drug delivery, related diagnostic and therapeutic biomarkers, and combinatory application strategies.
AB - IntroductionBiliary tract cancer (BTC) is a human malignancy with a poor prognosis. However, significant progress has been made in understanding the molecular mechanisms of carcinogenesis, leading to the development of targeted therapy strategies in recent years. The challenge now is to develop new therapeutic concepts to further increase the efficacy of BTC treatments in the coming years.Areas coveredThis review covers the emerging and advanced approaches of highly sophisticated antibody-drug conjugates (ADCs) and non-ADCs, particularly in relation to BTC. Additionally, the potential advantages and disadvantages of ADCs and non-ADCs regarding toxicities, bioavailability, and efficacy are presented and discussed.Expert opinionGiven the poor prognosis of BTCs, new targeted and precision therapy strategies using drug conjugates - with and without antibodies as drug carriers - have the potential to overcome the limitations of conventional chemotherapy by improving treatment specificity and efficacy while reducing systemic toxicity. However, several open questions remain regarding ADCs and non-ADCs, including chemical design, drug delivery, related diagnostic and therapeutic biomarkers, and combinatory application strategies.
KW - Biliary tract carcinomas
KW - Antibody drug conjugates
KW - Drug delivery system
KW - Drug development
KW - Non-antibody drug conjugates
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001471279000001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1080/14656566.2025.2493892
DO - 10.1080/14656566.2025.2493892
M3 - Review article
C2 - 40244683
SN - 1465-6566
VL - 26
SP - 887
EP - 896
JO - EXPERT OPINON ON PHARMACOTHERAPY
JF - EXPERT OPINON ON PHARMACOTHERAPY
IS - 7
ER -